BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 45 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $162,000 | -74.1% | 658,302 | -45.6% | 0.00% | – |
| Q2 2022 | $626,000 | -87.2% | 1,211,222 | -49.2% | 0.00% | – |
| Q1 2022 | $4,891,000 | -45.4% | 2,386,053 | +11.1% | 0.00% | – |
| Q4 2021 | $8,956,000 | -46.1% | 2,147,749 | +20.3% | 0.00% | – |
| Q3 2021 | $16,610,000 | -34.3% | 1,786,067 | +27.3% | 0.00% | -100.0% |
| Q2 2021 | $25,266,000 | +421000.0% | 1,402,891 | +92868.3% | 0.00% | – |
| Q1 2021 | $6,000 | – | 1,509 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Cypress Point Wealth Management, LLC | 471,878 | $8,499,000 | 6.04% |
| BALDWIN BROTHERS LLC/MA | 44,116 | $795,000 | 0.09% |
| DOWLING & YAHNKE LLC | 15,806 | $285,000 | 0.02% |
| INVERNESS COUNSEL LLC /NY/ | 13,307 | $240,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 15,000 | $270,000 | 0.01% |
| Cutler Group LLC / CA | 4,200 | $75,000 | 0.00% |
| MetLife Investment Management, LLC | 10,805 | $194,598 | 0.00% |
| HAP Trading, LLC | 13,900 | $64,000 | 0.00% |
| METROPOLITAN LIFE INSURANCE CO/NY | 8,272 | $148,979 | 0.00% |
| Ameritas Investment Partners, Inc. | 1,867 | $34,000 | 0.00% |